| 02/05/25 | 07:00:03 | 2 May 2025 | | Breztri met primary endpoints in Ph3 asthma trials | RNS |
| 01/05/25 | 16:00:00 | 1 May 2025 | | Director/PDMR Shareholding | RNS |
| 01/05/25 | 15:00:01 | 1 May 2025 | | Total Voting Rights | RNS |
| 29/04/25 | 07:10:02 | 29 Apr 2025 | | Fixed-duration Calquence recommended in EU for CLL | RNS |
| 29/04/25 | 07:05:01 | 29 Apr 2025 | | Update on CAPItello-280 Phase III trial | RNS |
| 29/04/25 | 07:00:09 | 29 Apr 2025 | | 1st Quarter Results | RNS |
| 22/04/25 | 07:00:13 | 22 Apr 2025 | | Enhertu combination improved PFS in 1L HER2+ mBC | RNS |
| 11/04/25 | 17:30:00 | 11 Apr 2025 | | Result of AGM | RNS |
| 04/04/25 | 07:05:00 | 4 Apr 2025 | | Imfinzi approved in EU for AEGEAN | RNS |
| 04/04/25 | 07:00:01 | 4 Apr 2025 | | Enhertu approved in EU in post-ET breast cancer | RNS |
| 01/04/25 | 15:00:00 | 1 Apr 2025 | | Total Voting Rights | RNS |
| 31/03/25 | 07:05:00 | 31 Mar 2025 | | Calquence recommended for EU approval in 1L MCL | RNS |
| 31/03/25 | 07:00:11 | 31 Mar 2025 | | Imfinzi approved in the US for bladder cancer | RNS |
| 21/03/25 | 10:58:49 | 21 Mar 2025 | | AZN invests $2.5bn in Beijing R&D & manufacturing | RNS |
| 17/03/25 | 07:10:01 | 17 Mar 2025 | | Eneboparatide Phase III trial met primary endpoint | RNS |
| 17/03/25 | 07:05:00 | 17 Mar 2025 | | Imfinzi approved in EU for limited-stage SCLC | RNS |
| 17/03/25 | 07:00:09 | 17 Mar 2025 | | AstraZeneca to acquire EsoBiotec | RNS |
| 12/03/25 | 18:00:00 | 12 Mar 2025 | | Holding(s) in Company | RNS |
| 07/03/25 | 15:00:00 | 7 Mar 2025 | | Director/PDMR Shareholding | RNS |
| 07/03/25 | 11:00:01 | 7 Mar 2025 | | Notice of AGM | RNS |
| 07/03/25 | 07:00:09 | 7 Mar 2025 | | Imfinzi improved EFS in early-stage gastric cancer | RNS |
| 06/03/25 | 15:00:01 | 6 Mar 2025 | | Director/PDMR Shareholding | RNS |
| 05/03/25 | 15:00:01 | 5 Mar 2025 | | Director/PDMR Shareholding | RNS |
| 03/03/25 | 15:00:00 | 3 Mar 2025 | | Total Voting Rights | RNS |
| 03/03/25 | 07:00:04 | 3 Mar 2025 | | Imfinzi recommended for EU approval for AEGEAN | RNS |
| 28/02/25 | 13:00:00 | 28 Feb 2025 | | Enhertu recommended in EU in post-ET breast cancer | RNS |
| 26/02/25 | 07:00:05 | 26 Feb 2025 | | Camizestrant improved PFS in 1L HR+ breast cancer | RNS |
| 19/02/25 | 07:00:06 | 19 Feb 2025 | | Filing of Form 20-F with SEC | RNS |
| 18/02/25 | 14:00:00 | 18 Feb 2025 | | Holding(s) in Company | RNS |
| 18/02/25 | 11:00:00 | 18 Feb 2025 | | Annual Financial Report | RNS |
| 18/02/25 | 07:00:07 | 18 Feb 2025 | | Directorate Change | RNS |
| 06/02/25 | 07:00:04 | 6 Feb 2025 | | Final Results | RNS |
| 03/02/25 | 17:00:00 | 3 Feb 2025 | | Total Voting Rights | RNS |
| 03/02/25 | 07:00:03 | 3 Feb 2025 | | Imfinzi recommended for EU approval for LS-SCLC | RNS |
| 28/01/25 | 07:00:07 | 28 Jan 2025 | | Enhertu approved in US for breast cancer post ET | RNS |
| 20/01/25 | 07:00:04 | 20 Jan 2025 | | Dato-DXd approved in US for HR+ breast cancer | RNS |
| 17/01/25 | 07:00:04 | 17 Jan 2025 | | Calquence combination approved in US for 1L MCL | RNS |
| 02/01/25 | 15:00:01 | 2 Jan 2025 | | Total Voting Rights | RNS |
| 24/12/24 | 07:00:04 | 24 Dec 2024 | | Dato-DXd NSQ NSCLC application withdrawn in EU | RNS |
| 23/12/24 | 07:00:05 | 23 Dec 2024 | | Tagrisso approved in EU based on LAURA trial | RNS |
| 16/12/24 | 07:00:06 | 16 Dec 2024 | | Directorate Change | RNS |
| 05/12/24 | 07:00:22 | 5 Dec 2024 | | Imfinzi approved in US for limited-stage SCLC | RNS |
| 04/12/24 | 13:45:00 | 4 Dec 2024 | | AstraZeneca appoints Iskra Reic EVP International | RNS |
| 02/12/24 | 15:05:00 | 2 Dec 2024 | | Block listing Interim Review | RNS |
| 02/12/24 | 15:00:00 | 2 Dec 2024 | | Total Voting Rights | RNS |
| 25/11/24 | 07:00:03 | 25 Nov 2024 | | Truqap improved rPFS in advanced prostate cancer | RNS |
| 20/11/24 | 16:00:00 | 20 Nov 2024 | | Director/PDMR Shareholding | RNS |
| 18/11/24 | 07:00:03 | 18 Nov 2024 | | Tagrisso recommended for EU approval - LAURA | RNS |
| 15/11/24 | 14:00:00 | 15 Nov 2024 | | Director/PDMR Shareholding | RNS |
| 15/11/24 | 10:00:00 | 15 Nov 2024 | | Director/PDMR Shareholding | RNS |
